- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Lixoft develops modeling and simulation software for advanced model-based drug development. Lixoft creates innovating tools for model-based drug development, fit for pharma & biotech companies, CROs, and for extensive deployment in any pharmaceutical workflow, from preclinical studies to final submission.
Monolix® is Lixoft's flagship product. Monolix allows the use of the most complex models in pharmacometrics. It offers a powerful, fast and easy solution for population analysis in mixed models in pre-clinical and clinical trials.
Lixoft's technologies are the result of a ten years research program in statistics and modeling, led by INRIA on non-linear mixed effect models for advanced population analysis, PK/PD, pre-clinical and clinical trial modeling & simulation.